An Evaluation of VYC ‐17. 5L for the Treatment of Marionette Lines: A Prospective, Open‐Label, Postmarketing Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Sofia Ruiz Del Cueto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Mira and Cueto, Madrid, Spain. Hauptthemen laut MEDLINE: Hyaluronic Acid, Dermal Fillers, Skin Aging, Lidocaine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Marionette lines are a feature of the aging face, descending from the oral commissures towards the jaw. VYC‐17.5 L is a dermal filler that contains 17.5 mg/mL of hyaluronic acid (HA) and lidocaine (3 mg/mL); it is intended for the treatment of skin depressions. VYC‐17.5 L has been shown to be safe and effective in different conditions, but there is a lack of published literature on its effectiveness in marionette lines.
Aims
This 12‐month prospective, open‐label, post‐marketing study evaluated the effectiveness and safety of the injectable HA filler VYC‐17.5 L for the improvement of marionette lines.
Methods
Adults (≥ 18 years) with mild‐to‐severe marionette lines on the validated Allergan Marionette Line Scale (AMLS) received VYC‐17.5 L on Day 1 with optional touch‐up on Day 14. The primary endpoint was proportion of participants with ≥ 1‐point change in AMLS from baseline at Month 1 (M1). Secondary endpoints were investigator‐ and participant‐rated Global Aesthetic Improvement Scale (GAIS), FACE‐Q satisfaction with facial appearance, and appraisal of lines: marionette. Safety was assessed throughout.
Results
A total of 83 participants completed the study; 69.9% of participants had ≥ 1‐point change in AMLS at M1. Investigator and participant GAIS showed improvement. Both FACE‐Q scores significantly improved from baseline ( p < 0.0001). A significant volume improvement was seen and maximized at M1. Most participant‐reported injection site reactions were mild or moderate and resolved within 8 days; 14 subjects reported adverse device effects, with the most common being pain, which resolved within 8 days.
Conclusion
This prospective, open‐label study showed that VYC‐17.5 L effectively improved marionette lines and was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clínica Mira and Cueto, Madrid, Spain.
- Instituto Médico Miramar, Málaga, Spain.
- GRITTI Chirurgia Maxillo Facciale, Milan, Italy.
- Private Practice, Torino, Italy.
- Allergan Aesthetics, an AbbVie Company, Madrid, Spain.
- Allergan Aesthetics, an AbbVie Company, Bucks, UK.
ORCID-Profile: Fernando Urdiales Galvez
Förderung
- AbbVie
Zitieren
APA
Cueto, S. R. D., Urdiales Galvez, F., Gritti, A., Kefalas, N., de la Guardia, C., & Kerson, G. (2025). An Evaluation of VYC ‐17. 5L for the Treatment of Marionette Lines: A Prospective, Open‐Label, Postmarketing Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16694
Vancouver
Cueto SRD, Urdiales Galvez F, Gritti A, Kefalas N, de la Guardia C, Kerson G. An Evaluation of VYC ‐17. 5L for the Treatment of Marionette Lines: A Prospective, Open‐Label, Postmarketing Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16694
BibTeX
@article{Cueto2025,
author = {Cueto, Sofia Ruiz Del and Urdiales Galvez, Fernando and Gritti, Alessandro and Kefalas, Nicola and de la Guardia, Carola and Kerson, Graeme},
title = {An Evaluation of VYC ‐17. 5L for the Treatment of Marionette Lines: A Prospective, Open‐Label, Postmarketing Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16694}
}
EUVIMED